181 related articles for article (PubMed ID: 34163368)
1. Engineering the
Sharrock AV; McManaway SP; Rich MH; Mumm JS; Hermans IF; Tercel M; Pruijn FB; Ackerley DF
Front Pharmacol; 2021; 12():701456. PubMed ID: 34163368
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the abilities of diverse nitroaromatic prodrug metabolites to exit a model Gram negative vector for bacterial-directed enzyme-prodrug therapy.
Chan-Hyams JVE; Copp JN; Smaill JB; Patterson AV; Ackerley DF
Biochem Pharmacol; 2018 Dec; 158():192-200. PubMed ID: 30352235
[TBL] [Abstract][Full Text] [Related]
3. Pseudomonas aeruginosa NfsB and nitro-CBI-DEI--a promising enzyme/prodrug combination for gene directed enzyme prodrug therapy.
Green LK; Syddall SP; Carlin KM; Bell GD; Guise CP; Mowday AM; Hay MP; Smaill JB; Patterson AV; Ackerley DF
Mol Cancer; 2013 Jun; 12():58. PubMed ID: 23758947
[TBL] [Abstract][Full Text] [Related]
4. The Flavin Reductase MsuE Is a Novel Nitroreductase that Can Efficiently Activate Two Promising Next-Generation Prodrugs for Gene-Directed Enzyme Prodrug Therapy.
Green LK; Storey MA; Williams EM; Patterson AV; Smaill JB; Copp JN; Ackerley DF
Cancers (Basel); 2013 Aug; 5(3):985-97. PubMed ID: 24202330
[TBL] [Abstract][Full Text] [Related]
5. E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954.
Vass SO; Jarrom D; Wilson WR; Hyde EI; Searle PF
Br J Cancer; 2009 Jun; 100(12):1903-11. PubMed ID: 19455141
[TBL] [Abstract][Full Text] [Related]
6. Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility.
Williams EM; Little RF; Mowday AM; Rich MH; Chan-Hyams JV; Copp JN; Smaill JB; Patterson AV; Ackerley DF
Biochem J; 2015 Oct; 471(2):131-53. PubMed ID: 26431849
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of NfsA-like nitroreductases from Neisseria meningitidis and Bartonella henselae for enzyme-prodrug therapy, targeted cellular ablation, and dinitrotoluene bioremediation.
Rich MH; Sharrock AV; Hall KR; Ackerley DF; MacKichan JK
Biotechnol Lett; 2018 Feb; 40(2):359-367. PubMed ID: 29147875
[TBL] [Abstract][Full Text] [Related]
8. Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954.
Prosser GA; Copp JN; Syddall SP; Williams EM; Smaill JB; Wilson WR; Patterson AV; Ackerley DF
Biochem Pharmacol; 2010 Mar; 79(5):678-87. PubMed ID: 19852945
[TBL] [Abstract][Full Text] [Related]
9. Characterisation of enzyme prodrug gene therapy combinations in coated spheroids and vascular networks in vitro.
Hunt MA; Li D; Hay MP; Currie MJ; Robinson BA; Patterson AV; Dachs GU
J Gene Med; 2012 Jan; 14(1):62-74. PubMed ID: 22147660
[TBL] [Abstract][Full Text] [Related]
10. The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite.
Bridgewater JA; Knox RJ; Pitts JD; Collins MK; Springer CJ
Hum Gene Ther; 1997 Apr; 8(6):709-17. PubMed ID: 9113510
[TBL] [Abstract][Full Text] [Related]
11. Studies on the nitroreductase prodrug-activating system. Crystal structures of complexes with the inhibitor dicoumarol and dinitrobenzamide prodrugs and of the enzyme active form.
Johansson E; Parkinson GN; Denny WA; Neidle S
J Med Chem; 2003 Sep; 46(19):4009-20. PubMed ID: 12954054
[TBL] [Abstract][Full Text] [Related]
12. Protocol for evaluating the abilities of diverse nitroaromatic prodrug metabolites to exit a model Gram negative bacterial vector.
Chan-Hyams JVE; Ackerley DF
MethodsX; 2020; 7():100797. PubMed ID: 32021829
[TBL] [Abstract][Full Text] [Related]
13. Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A.
Prosser GA; Copp JN; Mowday AM; Guise CP; Syddall SP; Williams EM; Horvat CN; Swe PM; Ashoorzadeh A; Denny WA; Smaill JB; Patterson AV; Ackerley DF
Biochem Pharmacol; 2013 Apr; 85(8):1091-103. PubMed ID: 23399641
[TBL] [Abstract][Full Text] [Related]
14. Repurposing
Ruiz de Garibay G; García de Jalón E; Stigen E; Lund KB; Popa M; Davidson B; Safont MM; Rygh CB; Espedal H; Barrett TM; Haug BE; McCormack E
Theranostics; 2021; 11(12):6044-6057. PubMed ID: 33897898
[TBL] [Abstract][Full Text] [Related]
15. Engineering
Williams EM; Rich MH; Mowday AM; Ashoorzadeh A; Copp JN; Guise CP; Anderson RF; Flanagan JU; Smaill JB; Patterson AV; Ackerley DF
Biochemistry; 2019 Sep; 58(35):3700-3710. PubMed ID: 31403283
[TBL] [Abstract][Full Text] [Related]
16. A mammalianized synthetic nitroreductase gene for high-level expression.
Grohmann M; Paulmann N; Fleischhauer S; Vowinckel J; Priller J; Walther DJ
BMC Cancer; 2009 Aug; 9():301. PubMed ID: 19712451
[TBL] [Abstract][Full Text] [Related]
17. Nitroreductase-based GDEPT.
Denny WA
Curr Pharm Des; 2002; 8(15):1349-61. PubMed ID: 12052212
[TBL] [Abstract][Full Text] [Related]
18. Interrogation of the Structure-Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications.
Ashoorzadeh A; Mowday AM; Guise CP; Silva S; Bull MR; Abbattista MR; Copp JN; Williams EM; Ackerley DF; Patterson AV; Smaill JB
Pharmaceuticals (Basel); 2022 Feb; 15(2):. PubMed ID: 35215297
[TBL] [Abstract][Full Text] [Related]
19. Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures.
Wilson WR; Pullen SM; Hogg A; Helsby NA; Hicks KO; Denny WA
Cancer Res; 2002 Mar; 62(5):1425-32. PubMed ID: 11888915
[TBL] [Abstract][Full Text] [Related]
20. Engineering a Multifunctional Nitroreductase for Improved Activation of Prodrugs and PET Probes for Cancer Gene Therapy.
Copp JN; Mowday AM; Williams EM; Guise CP; Ashoorzadeh A; Sharrock AV; Flanagan JU; Smaill JB; Patterson AV; Ackerley DF
Cell Chem Biol; 2017 Mar; 24(3):391-403. PubMed ID: 28262557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]